迪纳米克生物科技(天津)有限公司是由获京津冀生物医学人才的哈沃德医学院周泽奇博士创办的综合性生物医药国家高新技术企业。 Dynamiker成立于2014年3月,致力于侵袭性真菌病(IFD)诊断的研发、生产、临床应用和技术服务。 Dynamiker以打造IFD早期快速IVD产品国际知名品牌为使命,已成为IFD诊断领域的先驱。 Dynamiker 总部位于中新天津生态城,建立了国际化的研发和生产基地,并通过了 ISO13485 认证。迪纳米克先后荣获“国家高新技术企业”、“第四届中国创新创业大赛十佳”、“国务院重点侨创团队”、“全国十二五科技创新优秀奖”等多项奖项贡献奖”、“MOLSS最具潜力留学人员创业公司”、“天津市首批新兴产业龙头企业”、“天津市先进科技二等奖”、“全国模范院士专家工作站”等。 Dynamiker核心团队包括10余名博士和30名硕士,均来自知名生物制药公司或三级医院,具有丰富的研发、管理、生产和技术应用经验。 Dynamiker拥有IFD的关键核心技术和创新的Panel测试系统,建立了6个核心技术平台,包括:LAL产品开发平台、IFG多糖Ag&Ab制备平台、免疫学和自动化平台、微流体和POCT平台、分子诊断和MDR检测平台、临床转化平台。 Dynamiker已成功开发出20余款IVD产品及IFD自动化平台,其中6款面板检测产品具有国际前沿标准。 Dynamiker首次提出IFD的面板测试策略,是唯一一家可以独立提供所有产品的公司。面板测试使用方便,稳定性可靠,准确度高,抗干扰能力强,可实现对IFD的早期快速诊断和动态监测。它可以更准确地描述感染情况和阶段,为IFD的诊断和管理提供更准确可靠的证据。 作为CHIFNET的重要成员和GAFFI(全球真菌感染行动基金)的合作伙伴,Dynamiker面板检测产品已服务于国内30多个省和海外40多个国家的三级医院,并获得好评。强大的国际竞争力和巨大的发展潜力使Dynamiker迅速成长为IFD诊断领域的先驱。 Dynamiker遵循“技术就是生命”的原则,提出创新的面板检测方案,建立国际化、标准化、系列化的技术平台,为临床IFD诊断提供准确的参考依据。德纳迈克放眼全球,立足本土,与海外医疗机构建立战略合作,以卓越的产品开拓全球市场。 为成为全球IFD早期诊断的领先企业,Dynamiker正在筹备IPO,建立IFD前沿参考诊断实验室,打造更具竞争力的研发团队,打造IFD诊断与管理全生态产业链。 Dynamiker Bitechnology (Tianjin) Co.,Ltd is a comprehensive biomedical national high-tech enterprice, built by Dr. Zeqi Zhou from Harward Medical School, who is rewarded as Biomedical Talent of Jing-Jin-Ji. Established in March 2014, Dynamiker is dedicated to R&D, production, clinical application and technical service of Inavasive Fungal Disease (IFD) diagnosis. With the mission of building internation renowned brands for early and rapid IVD products for IFD, Dynamiker has become the global leader in IFD dianosis. With its headquarters in Sino-Singapore Tianjin Eco-City, Dynamiker has establised an international R&D and Production base, which is accredited by ISO13485. Dynamiker has won numbers of prizes like " National High-tech Enterprise","Top 10 of The Forth China Innovation &Enterpreneurship Competition","Key Overseas Chinese Entrepreneurial Team of The State Council"," National 12th Five-Year Science and Technology Innovation Outstanding Contrubution Award","MOLSS the Most Promising Overseas Students Venture Company", " Tianjin First Leading Enterprises Of Emerging Industry", " the Second Prize of Tianjin Advanced Science and Technology", " National Model Academician And Expert Workstation" and etc. The core team of Dynamiker, including more than 10 doctors and 30 masters, are all from famous biopharmaceutial companies or tertiary hospitals, and have rich experience in R&D, management, production and technology application. With it key core technologies and innovative Panel testing system for IFD, Dynamiker has set up 6 core technology platforms, including: LAL products development platform, IFG polusaccharide Ag & Ab preparation platform, Immunology and automation platform, Microfluidics and POCT platform, Molecular diagnosis and MDR detection platform, and clinic transformation platform. Dynamiker has successfully developed more than 20 IVD products and automation platform for IFD, 7 of which have filled the gap in the filed in China and 6 panel testing products with international cutting edge standard. Dynamiker firstly presents Panel testing strategy for IFD, and is the only company who can supply all the products independently. Panel testing is easy to use and has reliable stability, high accuracy and strong anti-interference, which could achieve early & rapid diagnosis and dynamic monitoring of IFD. It could describe the infection situation and phase more precisely, and provide more accurate and reliable evidence for diagnosis and management of IFD. As an important member of CHIFNET and partner of GAFFI( Global Action Fund for Fungal Infection), Dynamiker panel testing products have been serving tertiary hospitals in over 30 domestic provinces and 40 overseas countries with high praise. Strong international competitiveness and huge development potential make Dynamiker quickly grow into a leader in IFD diagnosis. Following the principle " Technology is life", Dynamiker puts forward innovative panel-testing scheme and establises international industrialization, standardization, serialization technology platforms offering accurate reference evidence for clinic IFD diagnosis. Thinking globally and acting locally, Dynamiker has established strategic cooperation with overseas medical institutions and explored the global market via excellent products. To become the global leading enterprise in early diagbosis of IFD, Dynamiker is preparing IPO, establishing cutting edge reference diagnostic laboratory for IFD, building more competitive R&D team, and building the whole eco industrial chain for IFD diagnosis and management.